India approves first dengue vaccine for persons aged 4-60
India's first dengue vaccine approval adds a preventive tool to the country's response against a recurring mosquito-borne public-health threat.
- India has approved its first dengue vaccine for people aged 4 to 60.
- Dengue prevention in India has relied mainly on vector control, surveillance, diagnosis, and clinical care.
- The dengue vaccine will be deployed through the immunization ecosystem after regulatory and rollout steps.
India has approved its first dengue vaccine for people aged 4 to 60. The approval matters because dengue remains a recurring mosquito-borne public-health challenge, and a vaccine can complement vector control, surveillance, and clinical care.
India will deploy the vaccine through the immunization ecosystem after appropriate regulatory and rollout steps. The immediate policy question is not only scientific efficacy, but also how quickly the vaccine can move from approval to safe and equitable public access.
What changed now
UPSC can frame India’s first dengue vaccine approval as a question on disease prevention, vaccine regulation, immunization delivery, and the public-health burden of vector-borne diseases. The topic also links biomedical innovation with health-system preparedness and rollout capacity.
Related dispatches
